Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3680042 | 0.99 | DRD2 (0.51) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL7473725 | 0.91 | DRD2 (0.47) | DRD2HTR1ADRD4HTR2AHTR2C | |
| Piclozotan SCHEMBL562627 | 0.91 | SIGMAR1 (0.54) | DRD2HTR1ADRD4HTR2AHTR2C | |
| Piclozotan SCHEMBL29379540 | 0.91 | SIGMAR1 (0.54) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL7467038 | 0.91 | DRD2 (0.48) | DRD2HTR1A | |
| SCHEMBL7470319 | 0.91 | DRD2 (0.50) | DRD2HTR1A | |
| Piclozotan SCHEMBL30249060 | 0.91 | SIGMAR1 (0.54) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL3675794 | 0.90 | DRD2 (0.45) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL7471246 | 0.90 | SIGMAR1 (0.53) | DRD2HTR1ADRD4HTR2AHTR2C | |
| SCHEMBL7472342 | 0.90 | DRD2 (0.49) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204202-A1 | DRUG FOR ALLEVIATING MOTOR COMPLICATIONS OR PSYCHIATRIC SYMPTOMS OF PARKINSON'S DISEASE | ASUBIO PHARMA CO., LTD. (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2213290-A1 | AGENT FOR IMPROVING MOTOR COMPLICATIONS OR PSYCHIATRIC SYMPTOMS IN PARKINSON'S DISEASE | Asubio Pharma Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-0925288-B1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LTD (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0755930-B1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LTD (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6337397-B1 | A BENZOXAZEPINE DERIVATIVE FOR TREATMENT OF ANXIETY NEUROSIS, PHOBIAS, OBSESSIVE-COMPULSIVE DISORDERS, SCHIZOPHRENIA, POST-CARDIAC TRAUMA STRESS DISORDERS, DEPRESSION DISORDERS, PSYCHOSOMATIC DISORDERS AND OTHER PSYCHONEUROTIC DISORDERS, | SUNTORY LIMITED (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6187769-B1 | Benzoxazepine derivatives and their salts and medicaments containing the same | SUNTORY LIMITED (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6114522-A | DEPROTONIZING A BEZOXAZEPINE DERIVATIVE WITH A BASE, REACTING THE DEPROTONIZED PRODUCT WITH A PHOSPHATE HALIDE TO PRODUCE AN INTERMEDIATE, REACTING INTERMEDIATE WITH A COMPLEX OF HALOGEN AND TRIALKYL OR ARYL PHOSPHINE | SUNTORY LIMITED (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0755930-A1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885HTR1A 7/4885DRD4 301/4885 |
| US-20100204202-A1 | DRUG FOR ALLEVIATING MOTOR COMPLICATIONS OR PSYCHIATRIC SYMPTOMS OF PARKINSON'S DISEASE | SLC6A3, HTR3A, PARK7 | DRD2 8/4885HTR1A 4/4885DRD4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.